2023
Increased HIV Transmissions With Reduced Insurance Coverage for HIV Preexposure Prophylaxis: Potential Consequences of Braidwood Management v. Becerra
Paltiel A, Ahmed A, Jin E, McNamara M, Freedberg K, Neilan A, Gonsalves G. Increased HIV Transmissions With Reduced Insurance Coverage for HIV Preexposure Prophylaxis: Potential Consequences of Braidwood Management v. Becerra. Open Forum Infectious Diseases 2023, 10: ofad139. PMID: 37008565, PMCID: PMC10061554, DOI: 10.1093/ofid/ofad139.Peer-Reviewed Original Research
2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis. Annals Of Internal Medicine 2020, 173: 507-508. PMID: 32926822, DOI: 10.7326/l20-0693.Peer-Reviewed Original Research
2019
New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP)
Walensky RP, Paltiel AD. New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP). JAMA Network Open 2019, 2: e195042. PMID: 31184696, DOI: 10.1001/jamanetworkopen.2019.5042.Peer-Reviewed Original Research
2006
The Survival Benefits of AIDS Treatment in the United States
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The Survival Benefits of AIDS Treatment in the United States. The Journal Of Infectious Diseases 2006, 194: 11-19. PMID: 16741877, DOI: 10.1086/505147.Peer-Reviewed Original ResearchConceptsSurvival benefitAntiretroviral therapyPotent combination antiretroviral therapyPneumocystis jiroveci pneumonia prophylaxisHIV disease treatmentImmunodeficiency syndrome careOpportunistic infection prophylaxisTotal survival benefitUntreated HIV diseaseCombination antiretroviral therapyEffective antiretroviral therapyPrevention of motherAbsence of treatmentYears of lifePneumonia prophylaxisChild transmissionInfant infectionAdult patientsHIV diseaseInfection prophylaxisDisease careNew diagnosisAIDS treatmentProphylaxisSurvival increase
2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfectionProphylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. JAMA Internal Medicine 2002, 162: 921-928. PMID: 11966344, DOI: 10.1001/archinte.162.8.921.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-Infective AgentsAntiprotozoal AgentsAtovaquoneCD4 Lymphocyte CountCost-Benefit AnalysisDapsoneDrug CostsHumansLife ExpectancyModels, TheoreticalNaphthoquinonesPentamidinePneumonia, PneumocystisPractice Guidelines as TopicQuality-Adjusted Life YearsConceptsQuality-adjusted life yearsCD4 cell countQuality-adjusted life expectancyPneumocystis carinii pneumoniaCD4 cell count increasePCP prophylaxisCell count increaseCell countCarinii pneumoniaClinical guidelinesCD4 cell count criteriaInitial CD4 cell countCD4 lymphocyte countPrimary PCP prophylaxisActive antiretroviral therapyCohort of HIVHuman immunodeficiency virusTMP/SMXCount increaseAntiretroviral therapyLymphocyte countHIV infectionImmunodeficiency virusTrimethoprim-sulfamethoxazoleProphylaxis
1998
Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS
Freedberg K, Paltiel A. Cost Effectiveness of Prophylaxis for Opportunistic Infections in AIDS. PharmacoEconomics 1998, 14: 165-173. PMID: 10186457, DOI: 10.2165/00019053-199814020-00005.Peer-Reviewed Original ResearchConceptsHIV patient careOpportunistic infectionsInfection preventionPatient careImmune system destructionSpecific opportunistic infectionsMajor opportunistic infectionNew antiretroviral therapiesQuality of lifeCost-effectiveness evaluationCost-effectiveness analysisCost effectivenessProphylaxis regimensAntiretroviral therapyHIV diseaseHIV infectionViral loadClinical guidelinesConsiderable financial strainProphylaxisClinical advancesViral replicationEffective agentInfectionHIVThe Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients
Paltiel A, Freedberg K. The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces 1998, 28: 34-51. DOI: 10.1287/inte.28.3.34.Peer-Reviewed Original ResearchIncidence of infectionLate-stage HIV diseaseToxicity of therapyNational cohort studyProgression of illnessCost-effectiveness resultsPrice of therapyCMV prophylaxisCytomegalovirus diseaseCytomegalovirus infectionHIV diseaseCohort studyPatients' qualityAIDS patientsClinical trialsNatural historyInfectionProphylaxisTherapyIncidenceDiseaseCompartmental modelPatientsIllnessProgression